Volume 122, Issue 2 , Pages 335-341.e3, August 2008
Airway hyperresponsiveness is dissociated from airway wall structural remodeling
Background
Nonasthmatic eosinophilic bronchitis (EB) has emerged as a useful tool to study the structural and inflammatory mechanisms of airway hyperresponsiveness (AHR) in asthma. We have previously shown that vascular remodeling and reticular basement membrane (RBM) thickening are present in EB. However, it is not known whether other features of structural remodeling including increased airway smooth muscle (ASM) mass, matrix deposition, and glandular hyperplasia are also present in EB.
Objectives
We sought to determine whether structural remodeling occurs in EB and is associated with AHR and airflow limitation.
Methods
Forty-two patients with asthma, 21 patients with EB, and 19 healthy volunteers were recruited. ASM area, RBM thickness, collagen 3 deposition, glandular area, mast cells, and granulocytes were assessed in bronchial biopsy samples.
Results
Nonasthmatic eosinophilic bronchitis and asthma were associated with a significant increase in ASM mass and RBM thickness compared with healthy subjects. In contrast, we did not observe any significant differences in collagen 3 deposition in the lamina propria and ASM or the % area of glands in the lamina propria. Univariate analysis demonstrated that mast cell numbers in the ASM were the only feature of remodeling associated with AHR (β = –0.51; P = .004). Stepwise linear regression revealed that a combination of mast cell numbers in the ASM (β = –0.43) and disease duration (β = –0.25; model-adjusted R2 = 0.26; P = .027) best modeled AHR.
Conclusion
Mast cell localization to the ASM bundle, but not structural remodeling of the airway wall, is associated with AHR in asthma.
Key words: Asthma, nonasthmatic eosinophilic bronchitis, airway hyperresponsiveness, mast cell, remodeling
Abbreviations used: AHR, Airway hyperresponsiveness, ASM, Airway smooth muscle, EB, Nonasthmatic eosinophilic bronchitis, GINA, Global Initiative for Asthma, RBM, Reticular basement membrane, UK, United Kingdom
Supported by Asthma UK, the Department of Health Clinician Scientist award, and a Wellcome Senior Clinical Fellowship (C.B.).
Disclosure of potential conflict of interest: I. Pavord is on the speakers' bureau for GlaxoSmithKline and AstraZeneca and has received research support from GlaxoSmithKline. C. Brightling is on the speakers' bureau for AstraZeneca, GlaxoSmithKline, and MSD; has received research support from GlaxoSmithKline, AstraZeneca, and Medimmune; and is on the scientific board at Medimmune. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(08)00956-1
doi:10.1016/j.jaci.2008.05.020
© 2008 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 122, Issue 2 , Pages 335-341.e3, August 2008
